Garay Arpa

October 17, 2026

Moderna faces stock dip amid cancer vaccine news and cash position. Recent articles note that Moderna holds a large cash reserve while advancing a deep cancer pipeline. A Phase 3 trial of its cancer vaccine reported positive results, which could broaden the company's product base. At the same time, the stock has fallen sharply, reflecting broader weakness in biotech and a pause in the recent rally. The decline occurs despite the cash strength and analyst price targets that remain well above current levels.

October 16, 2026

Merck Stock Rally Draws Attention to Valuation Concerns. Recent market commentary highlights a renewed confidence in Merck, with analysts debating whether the current rally has priced in too much optimism. While comparisons with peers like AbbVie and Bristol Myers Squibb focus on dividend yields and value, the primary discussion centers on the sustainability of Merck's recent price movement. The stock's high trailing P/E ratio of 112.6 provides context for these valuation concerns, suggesting that investors are closely monitoring if the current momentum can be sustained.